Published in:
Open Access
01-12-2008 | Research article
Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study
Authors:
Wendy Jeanneret-Sozzi, Alphonse Taghian, Ron Epelbaum, Philip Poortmans, Daniel Zwahlen, Beat Amsler, Sylviane Villette, Yazid Belkacémi, Tan Nguyen, Pierre Scalliet, Philippe Maingon, Cristina Gutiérrez, Pauline Gastelblum, Marco Krengli, Rita Abi Raad, Mahmut Ozsahin, René-Olivier Mirimanoff
Published in:
BMC Cancer
|
Issue 1/2008
Login to get access
Abstract
Background
To asses the clinical profile, treatment outcome and prognostic factors in primary breast lymphoma (PBL).
Methods
Between 1970 and 2000, 84 consecutive patients with PBL were treated in 20 institutions of the Rare Cancer Network. Forty-six patients had Ann Arbor stage IE, 33 stage IIE, 1 stage IIIE, 2 stage IVE and 2 an unknown stage. Twenty-one underwent a mastectomy, 39 conservative surgery and 23 biopsy; 51 received radiotherapy (RT) with (n = 37) or without (n = 14) chemotherapy. Median RT dose was 40 Gy (range 12–55 Gy).
Results
Ten (12%) patients progressed locally and 43 (55%) had a systemic relapse. Central nervous system (CNS) was the site of relapse in 12 (14%) cases. The 5-yr overall survival, lymphoma-specific survival, disease-free survival and local control rates were 53%, 59%, 41% and 87% respectively. In the univariate analyses, favorable prognostic factors were early stage, conservative surgery, RT administration and combined modality treatment. Multivariate analysis showed that early stage and the use of RT were favorable prognostic factors.
Conclusion
The outcome of PBL is fair. Local control is excellent with RT or combined modality treatment but systemic relapses, including that in the CNS, occurs frequently.